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HPV vaccination in HIV infection,  
Charles JN Lacey, University of York, UK 
 
Summary  
Persons with HIV are at increased risk of HPV infection, HPV disease, and HPV-related 
cancers compared to HIV negative persons. In persons with HIV, immune responses to 
vaccination are often sub-optimal, and while these improve with ART, they often remain 
lower and decline more rapidly than in HIV-negative individuals. Although the evidence base 
to support the immunogenicity of HPV vaccines in HIV+ve persons is reasonable, the 
evidence base to support the efficacy of HPV vaccines in HIV+ve individuals is inconsistent. 
There is one study in HIV+ve men who have sex with men (MSM) which showed no effect, 
and two other studies, one in HIV+ve women and one in HIV+ve adolescents that showed 
reduced effectiveness. All these effectiveness studies used Gardasil 4 (G4). Two studies in 
HIV+ve persons have shown superior immunogenicity of Cervarix (which uses a TLR4 agonist 
adjuvant) compared to G4. Studies of Hepatitis B vaccines in HIV+ve persons have shown 
that either (i) increased number of doses (ii) increased vaccine dose, or (iii) TLR agonist 
adjuvanted vaccines, all produce increased immunogenicity compared to standard vaccine 
regimes. Therefore, questions remain as to optimal HPV vaccine regimes in HIV and further 
clinical trials with different HPV vaccine regimes are needed. 
       
HIV and HPV 
HIV-1 is a retroviral infection that evolved ~ 120 years ago, and entered human populations 
> 60 years ago via a number of chimpanzee/gorilla ?to-human cross-species transmissions1, 
with the subsequent development of a worldwide pandemic. The key to the current degree 
of control of the pandemic was the development of triple antiretroviral therapy (ART), and 
its roll out to the developing world that began in the early 2000s. The most recent UNAIDS 
global estimates are that ~36.9 million are HIV-infected with ~19.5 million receiving ART. 
Persons with HIV, even when effectively treated with ART have an increased risk and rate of 
HPV acquisition, more frequent carriage of multiple HPV types, and an increased rate of 
HPV-related disease including more rapid progression to malignancies 2. Some of these 
ŝŶĐƌĞĂƐĞĚƌŝƐŬƐŵĂǇďĞ ‘ďĞŚĂǀŝŽƵƌĂů ?ĚƵĞƚŽ ŝŶĐreased HPV exposure pre-HIV, or on-going 
higher risk behaviour post-HIV acquisition. However, a fundamental part of the increased 
ƌŝƐŬŝƐ ‘ŝŵŵƵŶŽĚĞĨŝĐŝĞŶĐǇ ǀŝƌƵƐ-ĂƐƐŽĐŝĂƚĞĚ ?ĚƵĞƚŽ-cell, T-cell and NK-cell dysfunction, 
persistent inflammation, and persistent mucosal epithelial abnormalities3.     
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HPV vaccines have proved to have outstanding safety, efficacy and effectiveness in healthy 
immunocompetent young persons. Standard vaccination regimes for young girls and boys 
(aged 9 ?14 yrs) have already reduced from the originally licensed three doses to two doses, 
and there is now growing interest and a portfolio of trials evaluating whether one dose of 
HPV vaccine may be sufficient to induce long lasting protection in young healthy subjects4. 
However, HIV often reduces responsiveness to vaccines and their effectiveness 2,5,6. Even 
subjects who have been ART treated with suppressed viral loads  for > 5 years show specific 
defects in memory T Follicular Helper cell function leading to reduced B cell responses 7. 
However, these defects can be reversed in vitro by certain priming stimuli (e.g. anti-IL2, IL-
21). 
 
HPV vaccines in HIV 
According to our searches, there are only three published studies  of the efficacy / 
effectiveness of HPV vaccines in persons with HIV8-10. A placebo-controlled RCT of the 
effectiveness of G4 in adults >26 yrs in preventing anal HPV was stopped early for futility8.  
The study enrolled 575 US subjects (82% male, median age 47yrs, IQR 41-52yrs, median CD4 
606, 88% HIV VL <200) to receive G4 vaccine or placebo 1:1, stratified by sex and presence 
of anal biopsy HSIL. The 1* endpoint was vaccine efficacy (VE) against new persistent HPV 
6,11,16,18 (qHPV) anal infection, ± single final visit detection. VE against new persistent anal 
qHPV was 22% (95% CI -31% to 53%) which was not significant. High baseline HPV 
seropositivity was noted, which suggests that VE may have been compromised by prevalent 
sub-clinical / latent infections not detected at study entry.  
A Canadian study enrolled a cohort of 432 HIV+ve girls & women aged 9-65yrs (median age 
39yrs, IQR 34-45yrs, median CD4 500, 69% HIV VL <50) to receive 3 doses of G4 vaccine9. 
Two hundred and seventy nine women met the inclusion criteria for the 2yr follow up 
efficacy analyses (95.3% of those received 3 doses), comprising 279  ‘ŝŶƚĞŶƚŝŽŶ ƚŽƚƌĞĂƚ ?  ?ITT), 
 ? ? ? ‘ŶĂŢǀĞƚŽƌĞůĞǀĂŶƚƚǇƉĞ ?  ?EZd ? ?an  223  ‘ƉĞƌƉƌŽƚŽĐŽů ?  ?WW- 3 doses, NRT, data > 7 
month) populations. Incidence rates were: persistent qHPV 6/11/16/18 - ITT 2.3 /100py, PP 
1.0 /100py; genital warts - ITT 2.3 /100py, PP 1.0 /100py.  No cases of qHPV CIN2+ occurred 
in FU. The majority of the persistent qHPV in the ITT analysis was due to HPV18, and all 
cases in the PP analysis were due to HPV18. The persistent qHPV cases showed lower CD4 
counts (median 333), but similar anti-VLP antibody levels as non-failure cases.  
Comparison of rates of a combined endpoint of qHPV related infection and disease /100py 
with non-contemporary groups of qHPV vaccinated women and unvaccinated HIV+ve 
women aged 24-45yrs showed: vaccinated women without HIV - 0.1 /100py; vaccinated 
women with HIV  ? 1.2 /100py; unvaccinated women with HIV  ? 1.5 /100py. 
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A study of G4 vaccine effectiveness and HPV anti-VLP Ab levels in perinatally-HIV infected 
and uninfected youth has recently been accepted for publication10.   This was a prospective 
observational cohort of (a) perinatally HIV infected (PHIV, n=310) and (b) perinatally HIV 
exposed, uninfected (PHEU, n=148) girls & boys, 90% (PHIV) and 78% (PHEU) of whom 
received G4 vaccination. The mean age at first dose & length of FU was, PHIV = 13.7 yrs, 3.5 
yrs; PHEU = 12.4 yrs, 3.3yrs. 40% (PHIV) vs. 16% (PHEU) received at least 2 vaccine doses, 
and females were more likely to receive the full 3 dose course (46% PHIV, and 14% PHEU) 
compared with 6% and 0% of PHIV and PHEU males. 
Seroconversion to HPV 6, 11, 16 and 18 occurred in 83%, 84%, 90%, and 62% of vaccinated 
PHIV compared to 94%, 96%, 99%, and 87% of vaccinated PHEU respectively, (P<.05 for all 
comparisons). GMTs were lower in the PHIV vs PHEU within each category of G4 doses 
received. Higher GMTs were associated with younger age, lower HIV-1 RNA viral load, and 
higher CD4 % at first G4 vaccination. Abnormal cytology occurred in 33 of 56 PHIV and 1 of 7 
PHEU sexually active vaccinated females, yielding incidence rates per 100 person-years of 
15.0 (10.9 to 20.6) and 2.9 (0.4 to 22.3), respectively. There were marginal associations 
between lower CD4 %, HIV RNA >1,000 & not on ART and abnormal cytology (p <0.10 
>0.05), but not HPV Ab titre or number of doses. Genital warts occurred in 9 of 110 PHIV 
and 1 of 40 PHEU sexually active vaccinated females, yielding incidence rates per 100 
person-years of 1.7 (0.9 to 3.2) and 0.6 (0.1 to 4.4), respectively. 
All these three trials examining the effectiveness of HPV vaccines in HIV reflect patients 
receiving historic HIV treatment standards of care. That is, 78% of the adolescent HIV+ve 
cohort were born prior to 1998, and the median CD4 nadir in the Canadian female study 
was 230 and in the US / Brazil predominantly MSM study 256. Whether better effectiveness 
of HPV vaccines would be seen in patients who have started anti-retroviral therapy 
immediately after diagnosis is not known, but this should be investigated.          
There have been a number of studies examining the immunogenicity of HPV vaccines in 
persons with HIV and, in general, there is some reduction in HPV VLP antibody levels 
compared to HIV negative subjects10,11. Better immunogenicity is seen when HIV viral 
replication is controlled, and when there is no overt immunodeficiency2,12. Longitudinal data 
suggests somewhat reduced antibody persistence13,14, although modest memory B cell 
responses after G4 out to 4-5 years have been reported13, and vaccinated HIV+ve subjects 
respond to late boosting with a 4th dose14,15. 
An alternative HPV vaccine to G4 is Cervarix, a bivalent HPV 16/18 vaccine that uses the 
adjuvant AS04, a combination of the traditional adjuvant alum plus the TLR4 agonist 
monophosphoryl lipid A. A trial from Sweden showed superior immunogenicity of Cervarix 
compared to G4 in HIV16. Ninety one HIV+ve subjects (61 men, 30 women, median CD4 590, 
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88% on ARVs) were randomized 1:1 to Cervarix or G4 vaccine. All Cervarix recipients 
seroconverted at 1yr to HPV16 & HPV18; >95% of G4 recipients seroconverted to HPV 6, 11, 
& 16 and 73% to HPV18. Both vaccines induced cross-reactive antibodies (Luminex 
pseudovirion assay), greater in women than in men, but the spectrum was wider for 
Cervarix (31, 33, 35, 45, 56, 58) than for G4 (31, 35, 73). 
Recently the results of a 4 ?arm vaccine RCT in 257 HIV+ve (CD4 >350, women with both 
vertical and sexually transmission) & 289 HIV-ve women aged 15-25yrs were presented17. 
Both HIV +ve and HIV ?ve women were randomised 1:1 to Cervarix or G4, and serology was 
measured using a pseudovirion-based neutralizing antibody assay. At 24 months Cervarix 
was superior to G4 in the HIV positive females, for HPV16 by 2.74 fold (CIs 1.83-4.11) and for 
HPV 18 by 7.44 (4.79-11.54) in GMTs. Both CD4 cell and B memory cells were assayed out to 
12 months. In general, in HIV negative women, the cellular responses are similar to those of 
Einstein et al18, and again, in general, the responses in HIV+ve women are similar to those in 
HIV-ve women in this study. However, the exception was memory B cell responses against 
HPV 18 in HIV+ve women receiving G4, which were poor with median responses of 0 across 
the whole 12 month period (Berlaimont V, personal communication). Interestingly these 
poor anti-HPV18 responses appears to be in keeping with the data of McClymont et al9. 
Memory B cell priming induced by G4 to HPV 16 was also poor after the 1st dose with a 
medians of 0 spots. 
This data showing better immunogenicity in HIV with an additionally TLR agonist-adjuvanted 
vaccine compared to a classical alum-adjuvanted vaccine is in keeping with data obtained 
using different Hepatitis B virus (HBV) vaccines in HIV. The use of Fendrix (AS04 adjuvanted 
HBV vaccine) improves vaccine responses in HIV2. A randomised controlled trial of Engerix 
(alum-adjuvanted HBV vaccine) vs Engerix + a TLR9 adjuvant in HIV also showed superior 
immunogenicity of the TLR9-adjuvanted vaccine19. These data suggesting that TLR agonist-
adjuvanted vaccines might produce better responses in HIV patients are in keeping with the 
description that the specific defects in memory T Follicular Helper cell function in HIV could 
be reversed in vitro by priming stimuli such as anti-IL2 & IL-21 that stimulate the same 
MyD88 cellular transcription pathways as TLR agonists7. 
Therefore, both the McClymont et al data and ongoing immune deviation under ART raise 
the possibility that the observed potential lack of effectiveness with G4 in HIV is due to 
impaired cellular immunity and helper function rather than solely impaired antibody 
production. This leads to consideration of whether the use of Cervarix, which might 
overcome the Tfh defect, might produce better HPV vaccine effectiveness outcomes in 
persons with treated HIV. However, the obvious drawback is that Cervarix does not contain 
HPV 6/11 VLPs. Interestingly, Cervarix has been shown to induce cross-reactivity in heathy 
girls / women with a vaccine effectiveness of 34.5% against persistent HPV 6/11 at 48 
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months20, and also associated with a modest reduction in the incidence of genital warts in 
young girls in ecological observations21. However, this lack of solid protection against ano-
genital warts & HPV 6/11 could be overcome by using by using a mixed vaccination 
schedule, with initial Cervarix priming, such as Cervarix / Gardasil / Cervarix, or Cervarix / 
Cervarix / Gardasil. Recent data suggests that such mixed HPV vaccine regimes are indeed 
safe, effective, and induce solid antibody responses against all the HPV types in Gardasil 9 
(G9)22.      
In summary, in our opinion the lack of solid evidence of HPV vaccine effectiveness in HIV is 
of significant concern, and we propose that further clinical trials are needed. 
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